Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib +/- Dabrafenib in Pediatric Cancer
NCT02124772Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of trametinib in solid tumor, neuroblastoma, low-grade glioma (LGG) and 2 more (13 arms), sponsored by Novartis. Primary endpoints: Incidence of Treatment Emergent Adverse Events up to 64 months and Average Steady State Plasma Concentration. Started Jan 2015; status: completed.
02
Drugs
trametinib
03
Conditions
solid tumorneuroblastomalow-grade glioma (LGG)plexiform neurofibroma (PN)Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT02124772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124772.